Blue Lake Biotechnology Inc, a clinical-stage intranasal vaccine company, on Monday reported the presentation of interim data from the company's Phase 1/2a paediatric clinical trial of RSV vaccine candidate BLB201 as a late-breaking abstract at the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgium.
BLB201 is an intranasal RSV vaccine candidate being evaluated in Phase 1/2a clinical testing in children aged 8 to 59 months. It uses a proprietary PIV5 vector to express the RSV-F protein.
Interim data indicated that BLB201 may prevent symptomatic RSV infection in young children.
BLB201 has received Fast Track designation from the US Food and Drug Administration for prevention of RSV-associated acute respiratory disease in adults aged over 60 years and paediatric populations.
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Lupin Limited receives FDA approval for Phytonadione Injectable Emulsion USP
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Kedrion to be honoured at Premier's Supplier Innovation Celebration
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
FDA approves second Reykjavik manufacturing suite for AVT02
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA
Teva reports new ecopipam data showing tic reduction in Tourette syndrome